Horizon Pharma (HZNP) PT Bumped to $30 at BMO Capital Amid 'Very Solid' Q2
Tweet Send to a Friend
BMO Capital analyst Gary Nachman reiterated an Outperform rating and bumped his price target on Horizon Pharma (NASDAQ: HZNP) to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE